ResearcherShanghai University of Medicine and Health SciencesActive in the last 2 years

Pengcheng Chen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7989-0194; OpenAlex author ID A5101979964. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 13

Papers, trials and grants by year

2022: 1 paper · 2023: none · 2024: 1 paper

Papers 2

Targeting ONECUT3 blocks glycolytic metabolism and potentiates anti-PD-1 therapy in pancreatic cancer. Co-author DOI 10.1007/s13402-023-00852-3 ↗
Exploitation and Verification of a Stroma- and Metastasis-Associated Risk Prognostic Signature in Pancreatic Adenocarcinoma. Co-author DOI 10.3390/ph15111336 ↗

Closest collaborators

The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Run-Sheng Guo · 1 shared paper, 2024 · strength 0.22
- Paper Targeting ONECUT3 blocks glycolytic metabolism and potentiates anti-PD-1 therapy in pancreatic cancer. DOI 10.1007/s13402-023-00852-3 ↗
Shu‐Heng Jiang · 1 shared paper, 2024 · strength 0.22
- Paper Targeting ONECUT3 blocks glycolytic metabolism and potentiates anti-PD-1 therapy in pancreatic cancer. DOI 10.1007/s13402-023-00852-3 ↗
Yu-Heng Zhu · 1 shared paper, 2022 · strength 0.14
- Paper Exploitation and Verification of a Stroma- and Metastasis-Associated Risk Prognostic Signature in Pancreatic Adenocarci… DOI 10.3390/ph15111336 ↗
Jian‐Yu Yang · 1 shared paper, 2022 · strength 0.14
- Paper Exploitation and Verification of a Stroma- and Metastasis-Associated Risk Prognostic Signature in Pancreatic Adenocarci… DOI 10.3390/ph15111336 ↗
Li Chen · 1 shared paper, 2022 · strength 0.14
- Paper Exploitation and Verification of a Stroma- and Metastasis-Associated Risk Prognostic Signature in Pancreatic Adenocarci… DOI 10.3390/ph15111336 ↗
Zong‐Hao Duan · 1 shared paper, 2022 · strength 0.14
- Paper Exploitation and Verification of a Stroma- and Metastasis-Associated Risk Prognostic Signature in Pancreatic Adenocarci… DOI 10.3390/ph15111336 ↗
Jian Yang · 1 shared paper, 2022 · strength 0.14
- Paper Exploitation and Verification of a Stroma- and Metastasis-Associated Risk Prognostic Signature in Pancreatic Adenocarci… DOI 10.3390/ph15111336 ↗
Yongwei Sun · 1 shared paper, 2022 · strength 0.14
- Paper Exploitation and Verification of a Stroma- and Metastasis-Associated Risk Prognostic Signature in Pancreatic Adenocarci… DOI 10.3390/ph15111336 ↗
Pei‐Xuan Ji · 1 shared paper, 2022 · strength 0.14
- Paper Exploitation and Verification of a Stroma- and Metastasis-Associated Risk Prognostic Signature in Pancreatic Adenocarci… DOI 10.3390/ph15111336 ↗
Dejun Liu · 1 shared paper, 2022 · strength 0.14
- Paper Exploitation and Verification of a Stroma- and Metastasis-Associated Risk Prognostic Signature in Pancreatic Adenocarci… DOI 10.3390/ph15111336 ↗
Qin-Yuan Jia · 1 shared paper, 2022 · strength 0.14
- Paper Exploitation and Verification of a Stroma- and Metastasis-Associated Risk Prognostic Signature in Pancreatic Adenocarci… DOI 10.3390/ph15111336 ↗
Jia-Hao Zheng · 1 shared paper, 2022 · strength 0.14
- Paper Exploitation and Verification of a Stroma- and Metastasis-Associated Risk Prognostic Signature in Pancreatic Adenocarci… DOI 10.3390/ph15111336 ↗
Hong‐Fei Yao · 1 shared paper, 2022 · strength 0.14
- Paper Exploitation and Verification of a Stroma- and Metastasis-Associated Risk Prognostic Signature in Pancreatic Adenocarci… DOI 10.3390/ph15111336 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.